Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | $68.56M |
| Net Income (Most Recent Fiscal Year) | $-437.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 18.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.65 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -638.56% |
| Net Margin (Trailing 12 Months) | -638.88% |
| Return on Equity (Trailing 12 Months) | -49.31% |
| Return on Assets (Trailing 12 Months) | -38.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.54 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.16 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 139.52M |
| Free Float | 117.19M |
| Market Capitalization | $1.27B |
| Average Volume (Last 20 Days) | 6.25M |
| Beta (Past 60 Months) | 1.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 65.32% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |